Aluminum adjuvants may have potentially distinct roles in vaccine-related adverse events. - GreenMedInfo Summary
Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action.
Allergy Asthma Clin Immunol. 2018 ;14:80. Epub 2018 Nov 7. PMID: 30455719
Aluminium salts are by far the most commonly used adjuvants in vaccines. There are only two aluminium salts which are used in clinically-approved vaccines, Alhydrogeland AdjuPhos, while the novel aluminium adjuvant used in Gardasilis a sulphated version of the latter. We have investigated the physicochemical properties of these two aluminium adjuvants and specifically in milieus approximating to both vaccine vehicles and the composition of injection sites. Additionally we have used a monocytic cell line to establish the relationship between their physicochemical properties and their internalisation and cytotoxicity. We emphasise that aluminium adjuvants used in clinically approved vaccines are chemically and biologically dissimilar with concomitantly potentially distinct roles in vaccine-related adverse events.